A two-year study with the aim of preventing sternal wound
infections highlights SurgiClear as a key component of the
infection prevention bundle used to significantly reduce infection
rates
MISSISSAUGA, ON, Nov. 21,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced that its
SurgiClear® dressing played a key part in an
infection prevention bundle that significantly reduced surgical
wound infections in a two-year quality improvement study recently
published by Intermountain Primary Children's Hospital, a
not-for-profit children's hospital associated with the University of Utah and part of the Intermountain
Healthcare system.1 Intermountain Primary Children's
Hospital is recognized as one of the top children's hospitals in
the United States.
Describing the impact of the bundled intervention, published in
The Annals of Thoracic Surgery, the authors from
Intermountain Healthcare report that the annual rate of total
surgical wound infections decreased from 2.83% in 2019 to 1.15% in
2021. The bundled approach used to improve perioperative infection
prevention practices included implementation of SurgiClear as a
main practice change.
Jeremy Harman, PA-C, an author on
the study, commented, "The trifecta of breathable barrier
protection, antimicrobials, and the ability to monitor the site is
what makes this a great dressing. It's easier for us to assess the
wound and is more comfortable for patients."
The aim of the project was to reduce the rate of surgical wound
infections to less than 1.5% in pediatric cardiothoracic surgery
patients. Surgical wound infections are a common complication of
cardiac surgery, associated with increased length of hospital stay,
readmissions, higher cost of care and increased mortality.
Pediatric cardiology centers across the U.S. focusing on process
improvement are investing in preventative strategies and quality
improvement protocols to decrease the risk of surgical site
infections. Advanced technology, such as Covalon's SurgiClear, can
help to standardize post-operative wound care.
"It is great to see another institution sharing their experience
with our SurgiClear dressing through publication," said
Brian Pedlar, CEO. "At Covalon we're
committed to providing better experiences for patients and
clinicians, and this work completed by Intermountain Primary
Children's Hospital shows how the best practices and products come
together to do just that, helping the most vulnerable heal."
SurgiClear is a dual-antimicrobial clear silicone surgical
dressing that provides full site visibility, allowing for
inspection of surgical wound sites, while minimizing contact and
repetitive dressing removal. Its dual-antimicrobial silicone
technology allows for broad spectrum protection from both
gram-positive and gram-negative bacteria that is gentle on even the
most sensitive skin.
In addition to SurigClear, Covalon's other infection prevention
solutions include:
- VALGuard® - an FDA listed, transparent,
environmental barrier designed to protect catheter hubs and line
connections from external contaminants and gross contamination,
including body fluids and other secretions. It incorporates a
quick-release pull strip for fast access to infusion hubs and for
easy removal.
- IV Clear® - an antimicrobial vascular access
dressing that offers complete transparency at and around the
insertion site for easy daily assessment. It uses a soft silicone
adhesive to preserve the skin's barrier function and minimize skin
injuries and incorporates safe amounts of antimicrobials, without
sacrificing efficacy, to protect against chemical irritation.
Healthcare providers interested in learning more about Covalon's
solutions may visit www.covalon.com or follow Covalon on
LinkedIn, Facebook, Instagram or Twitter.
Reference
- Glenn, E. T., Harman, J. R., Marietta, J., Lake, J., Bailly, D.
K., Ou, Z., Griffiths, E. R., & Ware, A. L. (2022). Impact of a
Surgical Wound Infection Prevention Bundle in Pediatric
Cardiothoracic Surgery. The Annals of Thoracic Surgery.
https://doi.org/10.1016/j.athoracsur.2022.08.045
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The Company is
listed on the TSX Venture Exchange, having the symbol COV and
trades on the OTQX Market under the symbol CVALF. To learn more
about Covalon, visit our website at www.covalon.com
Website:
https://covalon.com/
Twitter: @covalon
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalons-surgiclear-dressing-plays-an-important-part-in-preventing-surgical-wound-infections-at-top-childrens-hospital-301683328.html
SOURCE Covalon Technologies Ltd.
